Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017, Article ID 5237634, 13 pages
https://doi.org/10.1155/2017/5237634
Research Article

Combined Analysis of Endothelial, Hematopoietic, and Mesenchymal Stem Cell Compartments Shows Simultaneous but Independent Effects of Age and Heart Disease

1Institute of Cardiology of Rio Grande do Sul, Fundação Universitária de Cardiologia, Av. Princesa Isabel 395, 90040-371 Porto Alegre, RS, Brazil
2Universidade Federal de Ciências da Saúde de Porto Alegre, Rua Sarmento Leite 245, 90050-170 Porto Alegre, RS, Brazil
3Laboratory of Stem Cells and Tissue Engineering, Universidade Luterana do Brasil, Av. Farroupilha 8001, 92425-900 Canoas, RS, Brazil

Correspondence should be addressed to Nance Beyer Nardi; moc.liamg@idranecnan

Received 5 March 2017; Revised 24 May 2017; Accepted 6 June 2017; Published 27 July 2017

Academic Editor: Tao-Sheng Li

Copyright © 2017 Carine Ghem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Orlic, J. Kajstura, S. Chimenti et al., “Bone marrow cells regenerate infarcted myocardium,” Nature, vol. 410, no. 6829, pp. 701–705, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. S. K. Sanganalmath and R. Bolli, “Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions,” Circulation Research, vol. 113, no. 6, pp. 810–834, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Kim, L. Shapiro, and A. Flynn, “The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease,” Pharmacology & Therapeutics, vol. 151, pp. 8–15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. S. A. Fisher, C. Doree, A. Mathur, D. P. Taggart, and E. Martin-Rendon, “Stem cell therapy for chronic ischaemic heart disease and congestive heart failure,” Cochrane Database of Systematic Reviews, vol. 12, article CD007888, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. P. K. Nguyen, J. W. Rhee, and J. C. Wu, “Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review,” JAMA Cardiology, vol. 1, no. 7, pp. 831–841, 2016. View at Publisher · View at Google Scholar
  6. O. Pfister, G. Della Verde, R. Liao, and G. M. Kuster, “Regenerative therapy for cardiovascular disease,” Translational Research, vol. 163, no. 4, pp. 307–320, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Musa, L. Z. Xin, V. Govindasamy, F. W. Fuen, and N. H. Kasim, “Global search for right cell type as a treatment modality for cardiovascular disease,” Expert Opinion on Biological Therapy, vol. 14, no. 1, pp. 63–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Li, N. Charif, D. Mainard, D. Bensoussan, J. F. Stoltz, and N. de Isla, “Donor’s age dependent proliferation decrease of human bone marrow mesenchymal stem cells is linked to diminished clonogenicity,” Bio-Medical Materials and Engineering, vol. 24, Supplement 1, pp. 47–52, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Rurali, B. Bassetti, G. L. Perrucci et al., “BM ageing: implication for cell therapy with EPCs,” Mechanisms of Ageing and Development, vol. 159, pp. 4–13, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Neef, Y. H. Choi, A. Weichel et al., “The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness,” Cytotherapy, vol. 14, no. 6, pp. 670–678, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. R. Mendelsohn and J. W. Larrick, “Rejuvenation of adult stem cells: is age-associated dysfunction epigenetic?” Rejuvenation Research, vol. 16, no. 2, pp. 152–157, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Hu, G. Yan, W. He, Z. Liu, H. Xu, and G. Ma, “The influence of disease and age on human cardiac stem cells,” Annals of Clinical Biochemistry, vol. 51, Part 5, pp. 582–590, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. D. D'Amario, A. M. Leone, A. Iaconelli et al., “Growth properties of cardiac stem cells are a novel biomarker of patients’ outcome after coronary bypass surgery,” Circulation, vol. 129, no. 2, pp. 157–172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. L. S. Meirelles and N. B. Nardi, “Methodology, biology and clinical applications of mesenchymal stem cells,” Frontiers in bioscience (Landmark edition), vol. 14, pp. 4281–4298, 2009. View at Google Scholar
  15. M. A. Deutsch, A. Sturzu, and S. M. Wu, “At a crossroad: cell therapy for cardiac repair,” Circulation Research, vol. 112, no. 6, pp. 884–890, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J. McMurray, S. Adamopoulos, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC,” European Journal of Heart Failure, vol. 14, no. 8, pp. 803–869, 2012. View at Google Scholar
  17. R. M. Lang, M. Bierig, R. B. Devereux et al., “Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology,” Journal of the American Society of Echocardiography, vol. 18, no. 12, pp. 1440–1463, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. S. A. Nashef, F. Roques, P. Michel, E. Gauducheau, S. Lemeshow, and R. Salamon, “European system for cardiac operative risk evaluation (EuroSCORE),” European Journal of Cardio-Thoracic Surgery, vol. 16, no. 1, pp. 9–13, 1999. View at Google Scholar
  19. P. W. Serruys, Y. Onuma, S. Garg et al., “Assessment of the SYNTAX score in the Syntax study,” EuroIntervention, vol. 5, no. 1, pp. 50–56, 2009. View at Publisher · View at Google Scholar
  20. J. M. Hill, G. Zalos, J. P. Halcox et al., “Circulating endothelial progenitor cells, vascular function, and cardiovascular risk,” The New England Journal of Medicine, vol. 348, no. 7, pp. 593–600, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. M. L. da Silva, P. C. Chagastelles, and N. B. Nardi, “Mesenchymal stem cells reside in virtually all post-natal organs and tissues,” Journal of Cell Science, vol. 119, Part 11, pp. 2204–2213, 2006. View at Google Scholar
  22. L. F. Diesel, B. P. dos Santos, B. C. Bellagamba et al., “Stability of reference genes during tri-lineage differentiation of human adipose-derived stromal cells,” Journal of Stem Cells, vol. 10, no. 4, pp. 225–242, 2015. View at Publisher · View at Google Scholar
  23. S. C. Smith, E. J. Benjamin, R. O. Bonow et al., “AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association,” Journal of the American College of Cardiology, vol. 58, no. 23, pp. 2432–2446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. L. S. Meirelles and N. B. Nardi, “Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization,” British Journal of Haematology, vol. 123, no. 4, pp. 702–711, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. L. M. de Macedo Braga, S. Lacchini, B. D. Schaan et al., “In situ delivery of bone marrow cells and mesenchymal stem cells improves cardiovascular function in hypertensive rats submitted to myocardial infarction,” Journal of Biomedical Science, vol. 15, no. 3, pp. 365–374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Marx, M. D. Silveira, I. Selbach et al., “Acupoint injection of autologous stromal vascular fraction and allogeneic adipose-derived stem cells to treat hip dysplasia in dogs,” Stem Cells International, vol. 2014, Article ID 391274, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Ahmadbeigi, M. Soleimani, F. Babaeijandaghi et al., “The aggregate nature of human mesenchymal stromal cells in native bone marrow,” Cytotherapy, vol. 14, no. 8, pp. 917–924, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. C. F. Markarian, G. Z. Frey, M. D. Silveira et al., “Isolation of adipose-derived stem cells: a comparison among different methods,” Biotechnology Letters, vol. 36, no. 4, pp. 693–702, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Bocelli-Tyndall, L. Bracci, G. Spagnoli et al., “Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro,” Rheumatology (Oxford, England), vol. 46, no. 3, pp. 403–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Castro-Malaspina, R. E. Gay, G. Resnick et al., “Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny,” Blood, vol. 56, no. 2, pp. 289–301, 1980. View at Google Scholar
  32. A. Stolzing, E. Jones, D. McGonagle, and A. Scutt, “Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies,” Mechanisms of Ageing and Development, vol. 129, no. 3, pp. 163–173, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. D. M. Choumerianou, G. Martimianaki, E. Stiakaki, L. Kalmanti, M. Kalmanti, and H. Dimitriou, “Comparative study of stemness characteristics of mesenchymal cells from bone marrow of children and adults,” Cytotherapy, vol. 12, no. 7, pp. 881–887, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Kornicka, K. Marycz, K. A. Tomaszewski, M. Marędziak, and A. Śmieszek, “The effect of age on osteogenic and adipogenic differentiation potential of human adipose derived stromal stem cells (hASCs) and the impact of stress factors in the course of the differentiation process,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 309169, 20 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. J. D. Kretlow, Y. Q. Jin, W. Liu et al., “Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells,” BMC Cell Biology, vol. 9, p. 60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. J. George, H. Shmilovich, V. Deutsch, H. Miller, G. Keren, and A. Roth, “Comparative analysis of methods for assessment of circulating endothelial progenitor cells,” Tissue Engineering, vol. 12, no. 2, pp. 331–335, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Tura, G. R. Barclay, H. Roddie, J. Davies, and M. L. Turner, “Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources,” Journal of Translational Medicine, vol. 5, p. 37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. Q. L. Hao, A. J. Shah, F. T. Thiemann, E. M. Smogorzewska, and G. M. Crooks, “A functional comparison of CD34+CD38- cells in cord blood and bone marrow,” Blood, vol. 86, no. 10, pp. 3745–3753, 1995. View at Google Scholar
  39. F. Lanza, D. Campioni, M. Punturieri et al., “In vitro assessment of bone marrow endothelial colonies (CFU-En) in non-Hodgkin’s lymphoma patients undergoing peripheral blood stem cell transplantation,” Bone Marrow Transplantation, vol. 32, no. 12, pp. 1165–1173, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Heeschen, R. Lehmann, J. Honold et al., “Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease,” Circulation, vol. 109, no. 13, pp. 1615–1622, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. I. Bozdag-Turan, R. G. Turan, L. Paranskaya et al., “Correlation between the functional impairment of bone marrow-derived circulating progenitor cells and the extend of coronary artery disease,” Journal of Translational Medicine, vol. 10, p. 143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. M. K. Adams, L. R. Goodrich, S. Rao et al., “Equine bone marrow-derived mesenchymal stromal cells (BMDMSCs) from the ilium and sternum: are there differences?” Equine Veterinary Journal, vol. 45, no. 3, pp. 372–375, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. J. D. Kisiday, L. R. Goodrich, C. W. McIlwraith, and D. D. Frisbie, “Effects of equine bone marrow aspirate volume on isolation, proliferation, and differentiation potential of mesenchymal stem cells,” American Journal of Veterinary Research, vol. 74, no. 5, pp. 801–807, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. U. Delling, K. Lindner, I. Ribitsch, H. Jülke, and W. Brehm, “Comparison of bone marrow aspiration at the sternum and the tuber coxae in middle-aged horses,” Canadian Journal of Veterinary Research, vol. 76, no. 1, pp. 52–56, 2012. View at Google Scholar
  45. G. J. Harker, R. A. Zbroja, J. Wass, P. C. Vincent, and F. O. Stephens, “Cell cycle homogeneity in bone marrow samples from different sites: flow cytometric evaluation of multiple samples from sheep,” Experimental Hematology, vol. 11, no. 10, pp. 1037–1041, 1983. View at Google Scholar
  46. J. Picchi, L. Trombi, L. Spugnesi et al., “HOX and TALE signatures specify human stromal stem cell populations from different sources,” Journal of Cellular Physiology, vol. 228, no. 4, pp. 879–889, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. C. P. Hsu, J. S. Wang, S. C. Hung, S. T. Lai, Z. C. Weng, and R. C. J. Chiu, “Human sternal mesenchymal stem cells: isolation, characterization and cardiomyogenic differentiation,” Acta Cardiologica Sinica, vol. 26, pp. 242–252, 2010. View at Google Scholar
  48. L. Koller, P. Hohensinner, P. Sulzgruber et al., “Prognostic relevance of circulating endothelial progenitor cells in patients with chronic heart failure,” Thrombosis and Haemostasis, vol. 116, no. 2, pp. 309–316, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Tournois, B. Pignon, M. A. Sevestre et al., “Cell therapy in critical limb ischemia: a comprehensive analysis of two cell therapy products,” Cytotherapy, vol. 19, no. 2, pp. 299–310, 2017. View at Publisher · View at Google Scholar · View at Scopus
  50. G. E. Schoeters and O. L. Vanderboroght, “Haemopoietic stem cell concentration and CFUs in DNA synthesis in bone marrow from different bone regions,” Experientia, vol. 36, no. 4, pp. 459–461, 1980. View at Publisher · View at Google Scholar · View at Scopus
  51. A. B. Araújo, M. H. Angeli, G. D. Salton, J. M. Furlan, T. Schmalfuss, and L. M. Röhsig, “Absolute density of different sources of hematopoietic progenitor cells: bone marrow, peripheral blood stem cell and umbilical cord blood,” Cytotherapy, vol. 19, no. 1, pp. 128–130, 2017. View at Publisher · View at Google Scholar
  52. T. Y. Wang, S. J. Chang, M. D. Chang, and H. W. Wang, “Unique biological properties and application potentials of CD34+ CD38- stem cells from various sources,” Taiwanese Journal of Obstetrics & Gynecology, vol. 48, no. 4, pp. 356–369, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Báez, B. Martín-Antonio, J. I. Piruat et al., “Gene and miRNA expression profiles of hematopoietic progenitor cells vary depending on their origin,” Biology of Blood and Marrow Transplantation, vol. 20, no. 5, pp. 630–639, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. K. S. Cohen, S. Cheng, M. G. Larson et al., “Circulating CD34(+) progenitor cell frequency is associated with clinical and genetic factors,” Blood, vol. 121, no. 8, pp. e50–e56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. O. M. Tepper, R. D. Galiano, J. M. Capla et al., “Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures,” Circulation, vol. 106, no. 22, pp. 2781–2786, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Chang, E. C. Forsberg, J. Wu et al., “Cholinergic activation of hematopoietic stem cells: role in tobacco-related disease?” Vascular Medicine, vol. 15, no. 5, pp. 375–385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Windecker, P. Kolh, F. Alfonso et al., “2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI),” European Heart Journal, vol. 35, no. 37, pp. 2541–2619, 2014. View at Google Scholar
  58. F. W. Mohr, M. C. Morice, A. P. Kappetein et al., “Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial,” Lancet, vol. 381, no. 9867, pp. 629–638, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Goichberg, R. Kannappan, M. Cimini et al., “Age-associated defects in EphA2 signaling impair the migration of human cardiac progenitor cells,” Circulation, vol. 128, no. 20, pp. 2211–2223, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. J. M. Hare, J. H. Traverse, T. D. Henry et al., “A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction,” Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277–2286, 2009. View at Google Scholar
  61. V. Y. Suncion, E. Ghersin, J. E. Fishman et al., “Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: an analysis from the percutaneous stem cell injection delivery effects on neomyogenesis (POSEIDON) randomized trial,” Circulation Research, vol. 114, no. 8, pp. 1292–1301, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringdén, “HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells,” Experimental Hematology, vol. 31, no. 10, pp. 890–896, 2003. View at Publisher · View at Google Scholar · View at Scopus